Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Ding, WG; Kitasato, H; Matsuura, H
   Involvement of calmodulin in glucagon-like peptide 1(7-36) amide-induced inhibition of the ATP-sensitive K+ channel in mouse pancreatic beta-cells
   EXPERIMENTAL PHYSIOLOGY
   
   W.G. Ding et al., "Involvement of calmodulin in glucagon-like peptide 1(7-36) amide-induced inhibition of the ATP-sensitive K+ channel in mouse pancreatic beta-cells", EXP PHYSIOL, 86(3), 2001, pp. 331-339
2. Gutniak, MK; Svartberg, J; Hellstrom, PM; Holst, JJ; Adner, N; Ahren, B
   Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes
   JOURNAL OF INTERNAL MEDICINE
   
   M.K. Gutniak et al., "Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes", J INTERN M, 250(1), 2001, pp. 81-87
3. Creutzfeldt, W
   The entero-insular axis in type 2 diabetes - incretins as therapeutic agents
   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
   
   W. Creutzfeldt, "The entero-insular axis in type 2 diabetes - incretins as therapeutic agents", EXP CL E D, 109, 2001, pp. S288-S303
4. Wettergren, A
   Glucagon-like peptide-1 - Gastrointestinal function and possible mechanismof action
   DANISH MEDICAL BULLETIN
   
   A. Wettergren, "Glucagon-like peptide-1 - Gastrointestinal function and possible mechanismof action", DAN MED B, 48(1), 2001, pp. 19-28
5. Vilsboll, T; Krarup, T; Madsbad, S; Holst, JJ
   No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose
   DIABETIC MEDICINE
   
   T. Vilsboll et al., "No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose", DIABET MED, 18(2), 2001, pp. 144-149
6. Bollag, RJ; Zhong, Q; Ding, KH; Phillips, P; Zhong, L; Qin, F; Cranford, J; Mulloy, AL; Cameron, R; Isales, CM
   Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects
   MOLECULAR AND CELLULAR ENDOCRINOLOGY
   
   R.J. Bollag et al., "Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects", MOL C ENDOC, 177(1-2), 2001, pp. 35-41
7. Fery, F; Deviere, J; Balasse, EO
   Metabolic handling of intraduodenal vs. intravenous glucose in humans
   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
   
   F. Fery et al., "Metabolic handling of intraduodenal vs. intravenous glucose in humans", AM J P-ENDO, 281(2), 2001, pp. E261-E268
8. Nakagawa, A; Azuma, S; Nakabayashi, H
   Novel gastroinsular axis involving a gastric transmural glucose flux and vagal mediation
   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
   
   A. Nakagawa et al., "Novel gastroinsular axis involving a gastric transmural glucose flux and vagal mediation", AM J P-ENDO, 281(2), 2001, pp. E304-E314
9. Edwards, CMB; Stanley, SA; Davis, R; Brynes, AE; Frost, GS; Seal, LJ; Ghatei, MA; Bloom, SR
   Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
   
   C.M.B. Edwards et al., "Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers", AM J P-ENDO, 281(1), 2001, pp. E155-E161
10. Tolessa, T; Naslund, E; Hellstrom, PM
    The inhibitory mechanism of GLP-1, but not glucagon, on fasted gut motility is dependent on the L-arginine/nitric oxide pathway
    REGULATORY PEPTIDES
    
    T. Tolessa et al., "The inhibitory mechanism of GLP-1, but not glucagon, on fasted gut motility is dependent on the L-arginine/nitric oxide pathway", REGUL PEPT, 98(1-2), 2001, pp. 33-40
11. Gebhard, B; Holst, JJ; Biegelmayer, C; Miholic, J
    Postprandial GLP-1, norepinephrine, and reactive hypoglycemia in dumping syndrome
    DIGESTIVE DISEASES AND SCIENCES
    
    B. Gebhard et al., "Postprandial GLP-1, norepinephrine, and reactive hypoglycemia in dumping syndrome", DIG DIS SCI, 46(9), 2001, pp. 1915-1923
12. Larsen, J; Hylleberg, B; Ng, K; Damsbo, P
    Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtainacceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment
    DIABETES CARE
    
    J. Larsen et al., "Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtainacceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment", DIABET CARE, 24(8), 2001, pp. 1416-1421
13. Holst, JJ; Orskov, C
    Incretin hormones - an update
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
    
    J.J. Holst e C. Orskov, "Incretin hormones - an update", SC J CL INV, 61, 2001, pp. 75-85
14. Toft-Nielsen, MB; Madsbad, S; Holst, JJ
    Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
    JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
    
    M.B. Toft-Nielsen et al., "Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes", J CLIN END, 86(8), 2001, pp. 3853-3860
15. Garcia-Flores, M; Zueco, JA; Alvarez, E; Blazquez, E
    Expression of glucagon-like peptide-1 (GLP-1) receptor and the effect of GLP-1-(7-36) amide on insulin release by pancreatic islets during rat ontogenic development
    EUROPEAN JOURNAL OF BIOCHEMISTRY
    
    M. Garcia-Flores et al., "Expression of glucagon-like peptide-1 (GLP-1) receptor and the effect of GLP-1-(7-36) amide on insulin release by pancreatic islets during rat ontogenic development", EUR J BIOCH, 268(3), 2001, pp. 514-520
16. Reimer, RA; Darimont, C; Gremlich, S; Nicolas-Metral, V; Ruegg, UT; Mace, K
    A human cellular model for studying the regulation of glucagon-like peptide-1 secretion
    ENDOCRINOLOGY
    
    R.A. Reimer et al., "A human cellular model for studying the regulation of glucagon-like peptide-1 secretion", ENDOCRINOL, 142(10), 2001, pp. 4522-4528
17. Ritzel, R; Schulte, M; Porksen, N; Nauck, MS; Holst, JJ; Juhl, C; Marz, W; Schmitz, O; Schmiegel, WH; Nauck, MA
    Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance
    DIABETES
    
    R. Ritzel et al., "Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance", DIABETES, 50(4), 2001, pp. 776-784
18. Vella, A; Shah, P; Basu, R; Basu, A; Camilleri, M; Schwenk, FW; Holst, JJ; Rizza, RA
    Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes
    DIABETES
    
    A. Vella et al., "Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes", DIABETES, 50(3), 2001, pp. 565-572
19. Vilsboll, T; Krarup, T; Deacon, CF; Madsbad, S; Holst, JJ
    Reduced postprandial concentrations of intact biologically active gluccagon-like peptide 1 in type 2 diabetic patients
    DIABETES
    
    T. Vilsboll et al., "Reduced postprandial concentrations of intact biologically active gluccagon-like peptide 1 in type 2 diabetic patients", DIABETES, 50(3), 2001, pp. 609-613
20. Meier, JJ; Huking, K; Holst, JJ; Deacon, CF; Schmiegel, WH; Nauck, MA
    Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes
    DIABETES
    
    J.J. Meier et al., "Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes", DIABETES, 50(11), 2001, pp. 2497-2504
21. Neidigh, JW; Fesinmeyer, RM; Prickett, KS; Andersen, NH
    Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states
    BIOCHEMISTRY
    
    J.W. Neidigh et al., "Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states", BIOCHEM, 40(44), 2001, pp. 13188-13200
22. Gin, H; Rigalleau, V
    Post-prandial hyperglycemia. post-prandial hyperglycemia and diabetes
    DIABETES & METABOLISM
    
    H. Gin e V. Rigalleau, "Post-prandial hyperglycemia. post-prandial hyperglycemia and diabetes", DIABETE MET, 26(4), 2000, pp. 265-272
23. D'Alessio, D
    Glucagon-like peptide 1 (GLP-1) in diabetes and aging
    JOURNAL OF ANTI-AGING MEDICINE
    
    D. D'Alessio, "Glucagon-like peptide 1 (GLP-1) in diabetes and aging", J ANTI-AG M, 3(3), 2000, pp. 329-333
24. Nauck, M; Hahn, S; Sauerwald, A; Schmiegel, W
    Lack of germline mutations in the preproglucagon gene region coding for glucagon-like peptide 1 in Type 2 diabetic (NIDDM) patients
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
    
    M. Nauck et al., "Lack of germline mutations in the preproglucagon gene region coding for glucagon-like peptide 1 in Type 2 diabetic (NIDDM) patients", EXP CL E D, 108(2), 2000, pp. 72-75
25. Hedetoft, C; Sheikh, SP; Larsen, S; Holst, JJ
    Effect of glucagon-like peptide 1(7-36)amide in insulin-treated patients with diabetes mellitus secondary to chronic pancreatitis
    PANCREAS
    
    C. Hedetoft et al., "Effect of glucagon-like peptide 1(7-36)amide in insulin-treated patients with diabetes mellitus secondary to chronic pancreatitis", PANCREAS, 20(1), 2000, pp. 25-31
26. Perfetti, R; Merkel, P
    Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function
    EUROPEAN JOURNAL OF ENDOCRINOLOGY
    
    R. Perfetti e P. Merkel, "Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function", EUR J ENDOC, 143(6), 2000, pp. 717-725
27. Balkan, B; Li, X
    Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms
    AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
    
    B. Balkan e X. Li, "Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms", AM J P-REG, 279(4), 2000, pp. R1449-R1454
28. Beuschlein, F; Borgemeister, M; Schirra, J; Goke, B; Fassnacht, M; Arlt, W; Allolio, B; Reincke, M
    Oral glucose tolerance testing but not intravenous glucose administration uncovers hyper-responsiveness of hypothalamo-pituitary-adrenal axis in patients with adrenal incidentalomas
    CLINICAL ENDOCRINOLOGY
    
    F. Beuschlein et al., "Oral glucose tolerance testing but not intravenous glucose administration uncovers hyper-responsiveness of hypothalamo-pituitary-adrenal axis in patients with adrenal incidentalomas", CLIN ENDOCR, 52(5), 2000, pp. 617-623
29. Persson, K; Gingerich, RL; Nayak, S; Wada, K; Wada, E; Ahren, B
    Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
    
    K. Persson et al., "Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice", AM J P-ENDO, 279(5), 2000, pp. E956-E962
30. Ebinger, M; Jehle, DR; Fussgaenger, RD; Fehmann, HC; Jehle, PM
    Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
    
    M. Ebinger et al., "Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes", AM J P-ENDO, 279(1), 2000, pp. E88-E94
31. Gallwitz, B; Ropeter, T; Morys-Wortmann, C; Mentlein, R; Siegel, EG; Schmidt, WE
    GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro
    REGULATORY PEPTIDES
    
    B. Gallwitz et al., "GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro", REGUL PEPT, 86(1-3), 2000, pp. 103-111
32. Nishizawa, M; Nakabayashi, H; Kawai, K; Ito, T; Kawakami, S; Nakagawa, A; Niijima, A; Uchida, K
    The hepatic vagal reception of intraportal GLP-1 is via receptor differentfrom the pancreatic GLP-1 receptor
    JOURNAL OF THE AUTONOMIC NERVOUS SYSTEM
    
    M. Nishizawa et al., "The hepatic vagal reception of intraportal GLP-1 is via receptor differentfrom the pancreatic GLP-1 receptor", J AUTON NER, 80(1-2), 2000, pp. 14-21
33. Ohnuma, H; Yamatani, K; Daimon, M; Igarashi, M; Manaka, H; Sasaki, H; Kato, T
    Impaired neural regulation of insulin secretion related to the leptin receptor gene mutation in Wistar fatty rats
    PHYSIOLOGY & BEHAVIOR
    
    H. Ohnuma et al., "Impaired neural regulation of insulin secretion related to the leptin receptor gene mutation in Wistar fatty rats", PHYSL BEHAV, 70(5), 2000, pp. 527-532
34. Heptulla, RA; Tamborlane, WV; Cavaghan, M; Bronson, M; Limb, C; Ma, YZ; Sherwin, RS; Caprio, S
    Augmentation of alimentary insulin secretion despite similar gastric inhibitory peptide (GIP) responses in juvenile obesity
    PEDIATRIC RESEARCH
    
    R.A. Heptulla et al., "Augmentation of alimentary insulin secretion despite similar gastric inhibitory peptide (GIP) responses in juvenile obesity", PEDIAT RES, 47(5), 2000, pp. 628-633
35. Knudsen, LB; Nielsen, PF; Huusfeldt, PO; Johansen, NL; Madsen, K; Pedersen, FZ; Thogersen, H; Wilken, M; Agerso, H
    Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
    JOURNAL OF MEDICINAL CHEMISTRY
    
    L.B. Knudsen et al., "Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration", J MED CHEM, 43(9), 2000, pp. 1664-1669
36. O'Harte, FPM; Mooney, MH; Kelly, CMN; Flatt, PR
    Improved glycaemic control in obese diabetic ob/ob mice using N-terminallymodified gastric inhibitory polypeptide
    JOURNAL OF ENDOCRINOLOGY
    
    F.P.M. O'Harte et al., "Improved glycaemic control in obese diabetic ob/ob mice using N-terminallymodified gastric inhibitory polypeptide", J ENDOCR, 165(3), 2000, pp. 639-648
37. Deacon, CF; Nauck, MA; Meier, J; Hucking, K; Holst, JJ
    Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
    JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
    
    C.F. Deacon et al., "Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide", J CLIN END, 85(10), 2000, pp. 3575-3581
38. Lugari, R; Dell'Anna, C; Ugolotti, D; Dei Cas, A; Barilli, AL; Zandomeneghi, R; Marani, B; Lotti, M; Orlandini, A; Gnudi, A
    Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes
    HORMONE AND METABOLIC RESEARCH
    
    R. Lugari et al., "Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes", HORMONE MET, 32(10), 2000, pp. 424-428
39. Schirra, J; Houck, P; Wank, U; Arnold, R; Goke, B; Katschinski, M
    Effects of glucagon-like peptide-1 (7-36) amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans
    GUT
    
    J. Schirra et al., "Effects of glucagon-like peptide-1 (7-36) amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans", GUT, 46(5), 2000, pp. 622-631
40. Fritsche, A; Stefan, N; Hardt, E; Schutzenauer, S; Haring, H; Stumvoll, M
    A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
    
    A. Fritsche et al., "A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility", EUR J CL IN, 30(5), 2000, pp. 411-418
41. Satoh, F; Beak, SA; Small, CJ; Falzon, M; Ghatei, MA; Bloom, SR; Smith, DM
    Characterization of human and rat glucagon-like peptide-1 receptors in theneurointermediate lobe: Lack of coupling to either stimulation or inhibition of adenylyl cyclase
    ENDOCRINOLOGY
    
    F. Satoh et al., "Characterization of human and rat glucagon-like peptide-1 receptors in theneurointermediate lobe: Lack of coupling to either stimulation or inhibition of adenylyl cyclase", ENDOCRINOL, 141(4), 2000, pp. 1301-1309
42. Bollag, RJ; Zhong, Q; Phillips, P; Min, L; Zhong, L; Cameron, R; Mulloy, AL; Rasmussen, H; Qin, F; Ding, KH; Isales, CM
    Osteoblast-derived cells express functional glucose dependent insulinotropic peptide receptors
    ENDOCRINOLOGY
    
    R.J. Bollag et al., "Osteoblast-derived cells express functional glucose dependent insulinotropic peptide receptors", ENDOCRINOL, 141(3), 2000, pp. 1228-1235
43. Seeley, RJ; Woods, SC; D'Alessio, D
    Editorial: Targeted gene disruption in endocrine research - The case of glucagon-like peptide-1 and neuroendocrine function
    ENDOCRINOLOGY
    
    R.J. Seeley et al., "Editorial: Targeted gene disruption in endocrine research - The case of glucagon-like peptide-1 and neuroendocrine function", ENDOCRINOL, 141(2), 2000, pp. 473-475
44. Lewis, JT; Dayanandan, B; Habener, JF; Kieffer, TJ
    Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: Demonstration by a receptor antagonist
    ENDOCRINOLOGY
    
    J.T. Lewis et al., "Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: Demonstration by a receptor antagonist", ENDOCRINOL, 141(10), 2000, pp. 3710-3716
45. Peracchi, M; Santangelo, A; Conte, D; Fraquelli, M; Tagliabue, R; Gebbia, C; Porrini, M
    The physical state of a meal affects hormone release and postprandial thermogenesis
    BRITISH JOURNAL OF NUTRITION
    
    M. Peracchi et al., "The physical state of a meal affects hormone release and postprandial thermogenesis", BR J NUTR, 83(6), 2000, pp. 623-628
46. Mojsov, S
    Glucagon-like peptide-1 (GLP-1) and the control of glucose metabolism in mammals and teleost fish
    AMERICAN ZOOLOGIST
    
    S. Mojsov, "Glucagon-like peptide-1 (GLP-1) and the control of glucose metabolism in mammals and teleost fish", AM ZOOLOG, 40(2), 2000, pp. 246-258
47. Brynes, AE; Edwards, CM; Jadhav, A; Ghatei, MA; Bloom, SR; Frost, GS
    Diet-induced change in fatty acid composition of plasma triacylglycerols is not associated with change in glucagon-like peptide 1 or insulin sensitivity in people with type 2 diabetes
    AMERICAN JOURNAL OF CLINICAL NUTRITION
    
    A.E. Brynes et al., "Diet-induced change in fatty acid composition of plasma triacylglycerols is not associated with change in glucagon-like peptide 1 or insulin sensitivity in people with type 2 diabetes", AM J CLIN N, 72(5), 2000, pp. 1111-1118
48. Ranganath, L; Schaper, F; Gama, R; Morgan, L; Wright, J; Teale, D; Marks, V
    Effect of glucagon on carbohydrate-mediated secretion of glucose-dependentinsulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-36 amide) (GLP-1)
    DIABETES-METABOLISM RESEARCH AND REVIEWS
    
    L. Ranganath et al., "Effect of glucagon on carbohydrate-mediated secretion of glucose-dependentinsulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-36 amide) (GLP-1)", DIABET M R, 15(6), 1999, pp. 390-394
49. Holst, JJ
    Glucagon-like peptide 1 (GLP-1): An intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential
    TRENDS IN ENDOCRINOLOGY AND METABOLISM
    
    J.J. Holst, "Glucagon-like peptide 1 (GLP-1): An intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential", TRENDS ENDO, 10(6), 1999, pp. 229-235
50. van der Burg, MPM; van Suylichem, PTR; Guicherit, OR; Frolich, M; Lemkes, HHPJ; Gooszen, HG
    The relative contribution of insulin secretory capacity, insulin action, and incretins to metabolic control after islet transplantation in dogs
    JOURNAL OF MOLECULAR MEDICINE-JMM
    
    M.P.M. van der Burg et al., "The relative contribution of insulin secretory capacity, insulin action, and incretins to metabolic control after islet transplantation in dogs", J MOL MED-J, 77(1), 1999, pp. 104-106
51. Holst, JJ
    Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential
    CURRENT MEDICINAL CHEMISTRY
    
    J.J. Holst, "Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential", CURR MED CH, 6(11), 1999, pp. 1005-1017
52. Naslund, E; Bogefors, J; Skogar, S; Gryback, P; Jacobsson, H; Holst, JJ; Hellstrom, PM
    GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYYrelease in humans
    AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
    
    E. Naslund et al., "GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYYrelease in humans", AM J P-REG, 46(3), 1999, pp. R910-R916
53. Carlsson, PO; Iwase, M; Jansson, L
    Stimulation of intestinal glucoreceptors in rats increases pancreatic islet blood flow through vagal mechanisms
    AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
    
    P.O. Carlsson et al., "Stimulation of intestinal glucoreceptors in rats increases pancreatic islet blood flow through vagal mechanisms", AM J P-REG, 45(1), 1999, pp. R233-R236
54. Tseng, CC; Zhang, XY; Wolfe, MM
    Effect of GIP and GLP-1 antagonists on insulin release in the rat
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
    
    C.C. Tseng et al., "Effect of GIP and GLP-1 antagonists on insulin release in the rat", AM J P-ENDO, 39(6), 1999, pp. E1049-E1054
55. Ahren, B; Pacini, G
    Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
    
    B. Ahren e G. Pacini, "Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice", AM J P-ENDO, 277(6), 1999, pp. E996-E1004
56. Brundin, T
    Splanchnic and extrasplanchnic extraction of insulin following oral and intravenous glucose loads
    CLINICAL SCIENCE
    
    T. Brundin, "Splanchnic and extrasplanchnic extraction of insulin following oral and intravenous glucose loads", CLIN SCI, 97(4), 1999, pp. 429-436
57. Livingston, JN; Schoen, WR
    Glucagon and glucagon-like peptide-1
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 34
    
    J.N. Livingston e W.R. Schoen, "Glucagon and glucagon-like peptide-1", ANNU REP M, 34, 1999, pp. 189-198
58. Chang, FY; Chen, TS; Lee, SD; Doong, ML; Wang, PS
    Misoprostol-inhibited rat gastric emptying is independent of gastric inhibitory polypeptide release
    PHARMACOLOGY
    
    F.Y. Chang et al., "Misoprostol-inhibited rat gastric emptying is independent of gastric inhibitory polypeptide release", PHARMACOL, 58(5), 1999, pp. 265-269
59. Meurer, JA; Colca, JR; Burton, PS; Elhammer, AP
    Properties of native and in vitro glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin(9-39)
    METABOLISM-CLINICAL AND EXPERIMENTAL
    
    J.A. Meurer et al., "Properties of native and in vitro glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin(9-39)", METABOLISM, 48(6), 1999, pp. 716-724
60. Kissler, HJ; Gepp, H; Schmiedl, A; Schwille, PO
    Preservation of the incretin effect after orthotopic pancreas transplantation in inbred rats
    METABOLISM-CLINICAL AND EXPERIMENTAL
    
    H.J. Kissler et al., "Preservation of the incretin effect after orthotopic pancreas transplantation in inbred rats", METABOLISM, 48(5), 1999, pp. 645-650
61. Freyse, EJ; Knospe, S; Becher, T; El Hag, O; Goke, B; Fischer, U
    Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic
    METABOLISM-CLINICAL AND EXPERIMENTAL
    
    E.J. Freyse et al., "Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic", METABOLISM, 48(1), 1999, pp. 134-137
62. Faulkner, A; Martin, PA
    Insulin secretion and intestinal peptides during lactation in sheep
    JOURNAL OF DAIRY RESEARCH
    
    A. Faulkner e P.A. Martin, "Insulin secretion and intestinal peptides during lactation in sheep", J DAIRY RES, 66(1), 1999, pp. 45-52
63. Edwards, CMB; Bloom, SR
    The incretins - outdated terminology in man?
    DIABETOLOGIA
    
    C.M.B. Edwards e S.R. Bloom, "The incretins - outdated terminology in man?", DIABETOLOG, 42(9), 1999, pp. 1148-1148
64. Nauck, MA
    Is glucagon-like peptide 1 an incretin hormone?
    DIABETOLOGIA
    
    M.A. Nauck, "Is glucagon-like peptide 1 an incretin hormone?", DIABETOLOG, 42(3), 1999, pp. 373-379
65. Nyholm, B; Walker, M; Gravholt, CH; Shearing, PA; Sturis, J; Alberti, KGMM; Holst, JJ; Schmitz, O
    Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations
    DIABETOLOGIA
    
    B. Nyholm et al., "Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations", DIABETOLOG, 42(11), 1999, pp. 1314-1323
66. Balkan, B; Kwasnik, L; Miserendino, R; Holst, JJ; Li, X
    Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obeseZucker rats
    DIABETOLOGIA
    
    B. Balkan et al., "Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obeseZucker rats", DIABETOLOG, 42(11), 1999, pp. 1324-1331
67. Edwards, CMB; Todd, JF; Mahmoudi, M; Wang, ZL; Wang, RM; Ghatei, MA; Bloom, SR
    Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans - Studies with the antagonist exendin 9-39
    DIABETES
    
    C.M.B. Edwards et al., "Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans - Studies with the antagonist exendin 9-39", DIABETES, 48(1), 1999, pp. 86-93
68. Hiroyoshi, M; Tateishi, K; Yasunami, Y; Maeshiro, K; Ono, J; Matsuoka, Y; Ikeda, S
    Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes
    AMERICAN JOURNAL OF GASTROENTEROLOGY
    
    M. Hiroyoshi et al., "Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes", AM J GASTRO, 94(4), 1999, pp. 976-981
69. Tammen, H; Forssmann, WG; Richter, R
    Proteolytic cleavage of glucagon-like peptide-1 by pancreatic beta cells and by fetal calf serum analyzed by mass spectrometry
    JOURNAL OF CHROMATOGRAPHY A
    
    H. Tammen et al., "Proteolytic cleavage of glucagon-like peptide-1 by pancreatic beta cells and by fetal calf serum analyzed by mass spectrometry", J CHROMAT A, 852(1), 1999, pp. 285-295
70. SIEGEL EG; GALLWITZ B; FOLSCH UR; SCHMIDT WE
    EFFECT OF HUMAN PANCREASTATIN PEPTIDE (HP-16) ON ORAL GLUCOSE-TOLERANCE IN MAN
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
    
    E.G. Siegel et al., "EFFECT OF HUMAN PANCREASTATIN PEPTIDE (HP-16) ON ORAL GLUCOSE-TOLERANCE IN MAN", EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 106(3), 1998, pp. 178-182
71. WILLMS B; IDOWU K; HOLST JJ; CREUTZFELDT W; NAUCK MA
    OVERNIGHT GLP-1 NORMALIZES FASTING BUT NOT DAYTIME PLASMA-GLUCOSE LEVELS IN NIDDM PATIENTS
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
    
    B. Willms et al., "OVERNIGHT GLP-1 NORMALIZES FASTING BUT NOT DAYTIME PLASMA-GLUCOSE LEVELS IN NIDDM PATIENTS", EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 106(2), 1998, pp. 103-107
72. NAUCK MA
    GLUCAGON-LIKE-PEPTIDE-1 (GLP-1) - A POTENT GUT HORMONE WITH A POSSIBLE THERAPEUTIC PERSPECTIVE
    Acta diabetologica
    
    M.A. Nauck, "GLUCAGON-LIKE-PEPTIDE-1 (GLP-1) - A POTENT GUT HORMONE WITH A POSSIBLE THERAPEUTIC PERSPECTIVE", Acta diabetologica, 35(3), 1998, pp. 117-129
73. KIMURA I; SASAMURA T; TSUNEKI H; IWAI M; FURUTA I; SASAMOTO H; FURUSAWA Y
    IMMUNOCYTOCHEMICAL LOCALIZATION OF SALIVARY PEPTIDE P-C IN HUMAN SUBMANDIBULAR-GLAND
    Biological & pharmaceutical bulletin
    
    I. Kimura et al., "IMMUNOCYTOCHEMICAL LOCALIZATION OF SALIVARY PEPTIDE P-C IN HUMAN SUBMANDIBULAR-GLAND", Biological & pharmaceutical bulletin, 21(5), 1998, pp. 506-512
74. BRYNES AE; FROST GS; EDWARDS MB; GHATEL MA; BLOOM SR
    PLASMA GLUCAGON-LIKE PEPTIDE-1(7-36) AMIDE (GLP-1) RESPONSE TO LIQUID-PHASE, SOLID-PHASE, AND MEALS OF DIFFERING LIPID-COMPOSITION
    Nutrition
    
    A.E. Brynes et al., "PLASMA GLUCAGON-LIKE PEPTIDE-1(7-36) AMIDE (GLP-1) RESPONSE TO LIQUID-PHASE, SOLID-PHASE, AND MEALS OF DIFFERING LIPID-COMPOSITION", Nutrition, 14(5), 1998, pp. 433-436
75. FEHMANN HC; PRACHT A; GOKE B
    HIGH-LEVEL EXPRESSION OF THE GLP-I RECEPTOR RESULTS IN RECEPTOR DESENSITIZATION
    Pancreas
    
    H.C. Fehmann et al., "HIGH-LEVEL EXPRESSION OF THE GLP-I RECEPTOR RESULTS IN RECEPTOR DESENSITIZATION", Pancreas, 17(3), 1998, pp. 309-314
76. NAITO H; SASAKI I; MATSUNO S
    SURGICAL ASPECT OF ENTEROINSULAR AXIS AFTER GASTROINTESTINAL SURGERY WITH REFERENCE TO INCRETIN SECRETION
    Pancreas
    
    H. Naito et al., "SURGICAL ASPECT OF ENTEROINSULAR AXIS AFTER GASTROINTESTINAL SURGERY WITH REFERENCE TO INCRETIN SECRETION", Pancreas, 16(3), 1998, pp. 370-378
77. SVARTBERG J; HOLST JJ; GUTNIAK M; ADNER N
    THE ETHANOL AUGMENTATION OF GLUCOSE-INDUCED INSULIN-SECRETION IS ABOLISHED BY CALCIUM ANTAGONISM WITH NIFEDIPINE - NO EVIDENCE FOR A ROLE OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1)
    Pancreas
    
    J. Svartberg et al., "THE ETHANOL AUGMENTATION OF GLUCOSE-INDUCED INSULIN-SECRETION IS ABOLISHED BY CALCIUM ANTAGONISM WITH NIFEDIPINE - NO EVIDENCE FOR A ROLE OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1)", Pancreas, 16(1), 1998, pp. 66-71
78. SEIFARTH C; BERGMANN J; HOLST JJ; RITZEL R; SCHMIEGEL W; NAUCK MA
    PROLONGED AND ENHANCED SECRETION OF GLUCAGON-LIKE PEPTIDE-1 (7-36 AMIDE) AFTER ORAL SUCROSE DUE TO ALPHA-GLUCOSIDASE INHIBITION (ACARBOSE) IN TYPE-2 DIABETIC-PATIENTS
    Diabetic medicine
    
    C. Seifarth et al., "PROLONGED AND ENHANCED SECRETION OF GLUCAGON-LIKE PEPTIDE-1 (7-36 AMIDE) AFTER ORAL SUCROSE DUE TO ALPHA-GLUCOSIDASE INHIBITION (ACARBOSE) IN TYPE-2 DIABETIC-PATIENTS", Diabetic medicine, 15(6), 1998, pp. 485-491
79. NAUCK MA; WEBER I; BACH I; RICHTER S; ORSKOV C; HOLST JJ; SCHMIEGEL W
    NORMALIZATION OF FASTING GLYCEMIA BY INTRAVENOUS GLP-1 ([7-36 AMIDE] OR [7-37]) IN TYPE-2 DIABETIC-PATIENTS
    Diabetic medicine
    
    M.A. Nauck et al., "NORMALIZATION OF FASTING GLYCEMIA BY INTRAVENOUS GLP-1 ([7-36 AMIDE] OR [7-37]) IN TYPE-2 DIABETIC-PATIENTS", Diabetic medicine, 15(11), 1998, pp. 937-945
80. SHALEV A; NINNIS R; KELLER U
    EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 (7-36 AMIDE) ON GLUCOSE KINETICS DURING SOMATOSTATIN-INDUCED SUPPRESSION OF INSULIN-SECRETION IN HEALTHY-MEN
    Hormone research
    
    A. Shalev et al., "EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 (7-36 AMIDE) ON GLUCOSE KINETICS DURING SOMATOSTATIN-INDUCED SUPPRESSION OF INSULIN-SECRETION IN HEALTHY-MEN", Hormone research, 49(5), 1998, pp. 221-225
81. MORGAN LM
    THE ROLE OF GASTROINTESTINAL HORMONES IN CARBOHYDRATE AND LIPID-METABOLISM AND HOMEOSTASIS - EFFECTS OF GASTRIC-INHIBITORY POLYPEPTIDE AND GLUCAGON-LIKE PEPTIDE-I
    Biochemical Society transactions
    
    L.M. Morgan, "THE ROLE OF GASTROINTESTINAL HORMONES IN CARBOHYDRATE AND LIPID-METABOLISM AND HOMEOSTASIS - EFFECTS OF GASTRIC-INHIBITORY POLYPEPTIDE AND GLUCAGON-LIKE PEPTIDE-I", Biochemical Society transactions, 26(2), 1998, pp. 216-222
82. WISHART JM; HOROWITZ M; MORRIS HA; JONES KL; NAUCK MA
    RELATION BETWEEN GASTRIC-EMPTYING OF GLUCOSE AND PLASMA-CONCENTRATIONS OF GLUCAGON-LIKE PEPTIDE-1
    Peptides (New York, N.Y. 1980)
    
    J.M. Wishart et al., "RELATION BETWEEN GASTRIC-EMPTYING OF GLUCOSE AND PLASMA-CONCENTRATIONS OF GLUCAGON-LIKE PEPTIDE-1", Peptides (New York, N.Y. 1980), 19(6), 1998, pp. 1049-1053
83. WETTERGREN A; PRIDAL L; WOJDEMANN M; HOLST JJ
    AMIDATED AND NON-AMIDATED GLUCAGON-LIKE PEPTIDE-1 (GLP-1) - NONPANCREATIC EFFECTS (CEPHALIC PHASE ACID-SECRETION) AND STABILITY IN PLASMA IN HUMANS
    Regulatory peptides
    
    A. Wettergren et al., "AMIDATED AND NON-AMIDATED GLUCAGON-LIKE PEPTIDE-1 (GLP-1) - NONPANCREATIC EFFECTS (CEPHALIC PHASE ACID-SECRETION) AND STABILITY IN PLASMA IN HUMANS", Regulatory peptides, 77(1-3), 1998, pp. 83-87
84. TODD JF; EDWARDS CMB; GHATEI MA; MATHER HM; BLOOM SR
    SUBCUTANEOUS GLUCAGON-LIKE PEPTIDE-I IMPROVES POSTPRANDIAL GLYCEMIC CONTROL OVER A 3-WEEK PERIOD IN PATIENTS WITH EARLY-TYPE-2 DIABETES
    Clinical science
    
    J.F. Todd et al., "SUBCUTANEOUS GLUCAGON-LIKE PEPTIDE-I IMPROVES POSTPRANDIAL GLYCEMIC CONTROL OVER A 3-WEEK PERIOD IN PATIENTS WITH EARLY-TYPE-2 DIABETES", Clinical science, 95(3), 1998, pp. 325-329
85. Edwards, CMB; Todd, JF; Ghatei, MA; Bloom, SR
    Subcutaneous glucagon-like peptide-I (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects
    CLINICAL SCIENCE
    
    C.M.B. Edwards et al., "Subcutaneous glucagon-like peptide-I (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects", CLIN SCI, 95(6), 1998, pp. 719-724
86. SCHIRRA J; LEICHT P; HILDEBRAND P; BEGLINGER C; ARNOLD R; GOKE B; KATSCHINSKI M
    MECHANISMS OF THE ANTIDIABETIC ACTION OF SUBCUTANEOUS GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS
    Journal of Endocrinology
    
    J. Schirra et al., "MECHANISMS OF THE ANTIDIABETIC ACTION OF SUBCUTANEOUS GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS", Journal of Endocrinology, 156(1), 1998, pp. 177-186
87. SCHIRRA J; STURM K; LEICHT P; ARNOLD R; GOKE B; KATSCHINSKI M
    EXENDIN(9-39)AMIDE IS AN ANTAGONIST OF GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE IN HUMANS
    The Journal of clinical investigation
    
    J. Schirra et al., "EXENDIN(9-39)AMIDE IS AN ANTAGONIST OF GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE IN HUMANS", The Journal of clinical investigation, 101(7), 1998, pp. 1421-1430
88. FLINT A; RABEN A; ASTRUP A; HOLST JJ
    GLUCAGON-LIKE PEPTIDE-1 PROMOTES SATIETY AND SUPPRESSES ENERGY-INTAKEIN HUMANS
    The Journal of clinical investigation
    
    A. Flint et al., "GLUCAGON-LIKE PEPTIDE-1 PROMOTES SATIETY AND SUPPRESSES ENERGY-INTAKEIN HUMANS", The Journal of clinical investigation, 101(3), 1998, pp. 515-520
89. SCROCCHI LA; DRUCKER DJ
    EFFECTS OF AGING AND A HIGH-FAT DIET ON BODY-WEIGHT AND GLUCOSE-TOLERANCE IN GLUCAGON-LIKE PEPTIDE-1 RECEPTOR(- -) MICE/
    Endocrinology
    
    L.A. Scrocchi e D.J. Drucker, "EFFECTS OF AGING AND A HIGH-FAT DIET ON BODY-WEIGHT AND GLUCOSE-TOLERANCE IN GLUCAGON-LIKE PEPTIDE-1 RECEPTOR(- -) MICE/", Endocrinology, 139(7), 1998, pp. 3127-3132
90. SERRE V; DOLCI W; SCHAERER E; SCROCCHI L; DRUCKER D; EFRAT S; THORENS B
    EXENDIN-(9-39) IS AN INVERSE AGONIST OF THE MURINE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR - IMPLICATIONS FOR BASAL INTRACELLULAR CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE LEVELS AND BETA-CELL GLUCOSE COMPETENCE
    Endocrinology
    
    V. Serre et al., "EXENDIN-(9-39) IS AN INVERSE AGONIST OF THE MURINE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR - IMPLICATIONS FOR BASAL INTRACELLULAR CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE LEVELS AND BETA-CELL GLUCOSE COMPETENCE", Endocrinology, 139(11), 1998, pp. 4448-4454
91. BRUBAKER PL; SCHLOOS J; DRUCKER DJ
    REGULATION OF GLUCAGON-LIKE PEPTIDE-1 SYNTHESIS AND SECRETION IN THE GLUTAG ENTEROENDOCRINE CELL-LINE
    Endocrinology
    
    P.L. Brubaker et al., "REGULATION OF GLUCAGON-LIKE PEPTIDE-1 SYNTHESIS AND SECRETION IN THE GLUTAG ENTEROENDOCRINE CELL-LINE", Endocrinology, 139(10), 1998, pp. 4108-4114
92. TOFTNIELSEN M; MADSBAD S; HOLST JJ
    EXAGGERATED SECRETION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) COULD CAUSE REACTIVE HYPOGLYCEMIA
    Diabetologia
    
    M. Toftnielsen et al., "EXAGGERATED SECRETION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) COULD CAUSE REACTIVE HYPOGLYCEMIA", Diabetologia, 41(10), 1998, pp. 1180-1186
93. CORDIERBUSSAT M; BERNARD C; LEVENEZ F; KLAGES N; LASERRITZ B; PHILIPPE J; CHAYVIALLE JA; CUBER JC
    PEPTONES STIMULATE BOTH THE SECRETION OF THE INCRETIN HORMONE GLUCAGON-LIKE PEPTIDE-1 AND THE TRANSCRIPTION OF THE PROGLUCAGON GENE
    Diabetes
    
    M. Cordierbussat et al., "PEPTONES STIMULATE BOTH THE SECRETION OF THE INCRETIN HORMONE GLUCAGON-LIKE PEPTIDE-1 AND THE TRANSCRIPTION OF THE PROGLUCAGON GENE", Diabetes, 47(7), 1998, pp. 1038-1045
94. SCROCCHI LA; MARSHALL BA; COOK SM; BRUBAKER PL; DRUCKER DJ
    IDENTIFICATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ACTIONS ESSENTIAL FOR GLUCOSE-HOMEOSTASIS IN MICE WITH DISRUPTION OF GLP-1 RECEPTOR SIGNALING
    Diabetes
    
    L.A. Scrocchi et al., "IDENTIFICATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ACTIONS ESSENTIAL FOR GLUCOSE-HOMEOSTASIS IN MICE WITH DISRUPTION OF GLP-1 RECEPTOR SIGNALING", Diabetes, 47(4), 1998, pp. 632-639
95. HOLST JJ; DEACON CF
    INHIBITION OF THE ACTIVITY OF DIPEPTIDYL-PEPTIDASE-IV AS A TREATMENT FOR TYPE-2 DIABETES
    Diabetes
    
    J.J. Holst e C.F. Deacon, "INHIBITION OF THE ACTIVITY OF DIPEPTIDYL-PEPTIDASE-IV AS A TREATMENT FOR TYPE-2 DIABETES", Diabetes, 47(11), 1998, pp. 1663-1670
96. LAVIN JH; WITTERT GA; ANDREWS J; YEAP B; WISHART JM; MORRIS HA; MORLEY JE; HOROWITZ M; READ NW
    INTERACTION OF INSULIN, GLUCAGON-LIKE PEPTIDE-1, GASTRIC-INHIBITORY POLYPEPTIDE, AND APPETITE IN RESPONSE TO INTRADUODENAL CARBOHYDRATE
    The American journal of clinical nutrition
    
    J.H. Lavin et al., "INTERACTION OF INSULIN, GLUCAGON-LIKE PEPTIDE-1, GASTRIC-INHIBITORY POLYPEPTIDE, AND APPETITE IN RESPONSE TO INTRADUODENAL CARBOHYDRATE", The American journal of clinical nutrition, 68(3), 1998, pp. 591-598
97. SCHIRRA J; KUWERT P; WANK U; LEICHT P; ARNOLD R; GOKE B; KATSCHINSKI M
    DIFFERENTIAL-EFFECTS OF SUBCUTANEOUS GLP-1 ON GASTRIC-EMPTYING, ANTRODUODENAL MOTILITY, AND PANCREATIC FUNCTION IN MEN
    Proceedings of the Association of American Physicians
    
    J. Schirra et al., "DIFFERENTIAL-EFFECTS OF SUBCUTANEOUS GLP-1 ON GASTRIC-EMPTYING, ANTRODUODENAL MOTILITY, AND PANCREATIC FUNCTION IN MEN", Proceedings of the Association of American Physicians, 109(1), 1997, pp. 84-97
98. DEORE K; GREIG NH; HOLLOWAY HW; WANG YH; PERFETTI R; EGAN JM
    THE EFFECTS OF GLP-1 ON INSULIN RELEASE IN YOUNG AND OLD RATS IN THE FASTING STATE AND DURING AN INTRAVENOUS GLUCOSE-TOLERANCE TEST
    The journals of gerontology. Series A, Biological sciences and medical sciences
    
    K. Deore et al., "THE EFFECTS OF GLP-1 ON INSULIN RELEASE IN YOUNG AND OLD RATS IN THE FASTING STATE AND DURING AN INTRAVENOUS GLUCOSE-TOLERANCE TEST", The journals of gerontology. Series A, Biological sciences and medical sciences, 52(5), 1997, pp. 245-249
99. EDWARDS CMB; EDWARDS AV; BLOOM SR
    CARDIOVASCULAR AND PANCREATIC ENDOCRINE RESPONSES TO GLUCAGON-LIKE PEPTIDE-1(7-36) AMIDE IN THE CONSCIOUS CALF
    Experimental physiology
    
    C.M.B. Edwards et al., "CARDIOVASCULAR AND PANCREATIC ENDOCRINE RESPONSES TO GLUCAGON-LIKE PEPTIDE-1(7-36) AMIDE IN THE CONSCIOUS CALF", Experimental physiology, 82(4), 1997, pp. 709-716
100. WANG Y; KOLE HK; MONTROSERAFIZADEH C; PERFETTI R; BERNIER M; EGAN JM
     REGULATION OF GLUCOSE TRANSPORTERS AND HEXOSE UPTAKE IN 3T3-L1 ADIPOCYTES - GLUCAGON-LIKE PEPTIDE-1 AND INSULIN INTERACTIONS
     Journal of molecular endocrinology
     
     Y. Wang et al., "REGULATION OF GLUCOSE TRANSPORTERS AND HEXOSE UPTAKE IN 3T3-L1 ADIPOCYTES - GLUCAGON-LIKE PEPTIDE-1 AND INSULIN INTERACTIONS", Journal of molecular endocrinology, 19(3), 1997, pp. 241-248